Trial · NCT04110145
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Treatment Period (4 Weeks) | STARTED | Cohort 1 (Linaclotide 18 μg) | 7 | |
| Double-Blind Treatment Period (4 Weeks) | STARTED | Cohort 2 (Linaclotide 36 μg) | 7 | |
| Double-Blind Treatment Period (4 Weeks) | STARTED | Cohort 3 (Linaclotide 72 μg) | 6 | |
| Double-Blind Treatment Period (4 Weeks) | STARTED | Final Cohort (Linaclotide 72 μg) | 7 | |
| Double-Blind Treatment Period (4 Weeks) | STARTED | Placebo Pooled | 8 | |
| Double-Blind Treatment Period (4 Weeks) | COMPLETED | Cohort 1 (Linaclotide 18 μg) | 7 | |
| Double-Blind Treatment Period (4 Weeks) | COMPLETED | Cohort 2 (Linaclotide 36 μg) | 7 | |
| Double-Blind Treatment Period (4 Weeks) | COMPLETED | Cohort 3 (Linaclotide 72 μg) | 6 | |
| Double-Blind Treatment Period (4 Weeks) | COMPLETED | Final Cohort (Linaclotide 72 μg) | 6 | |
| Double-Blind Treatment Period (4 Weeks) | COMPLETED | Placebo Pooled | 8 | |
| Double-Blind Treatment Period (4 Weeks) | NOT COMPLETED | Cohort 1 (Linaclotide 18 μg) | 0 | |
| Double-Blind Treatment Period (4 Weeks) | NOT COMPLETED | Cohort 2 (Linaclotide 36 μg) | 0 | |
| Double-Blind Treatment Period (4 Weeks) | NOT COMPLETED | Cohort 3 (Linaclotide 72 μg) | 0 | |
| Double-Blind Treatment Period (4 Weeks) | NOT COMPLETED | Final Cohort (Linaclotide 72 μg) | 1 | |
| Double-Blind Treatment Period (4 Weeks) | NOT COMPLETED | Placebo Pooled | 0 | |
| Post-Treatment Period (1 Week) | STARTED | Cohort 1 (Linaclotide 18 μg) | 7 | |
| Post-Treatment Period (1 Week) | STARTED | Cohort 2 (Linaclotide 36 μg) | 7 | |
| Post-Treatment Period (1 Week) | STARTED | Cohort 3 (Linaclotide 72 μg) | 5 | |
| Post-Treatment Period (1 Week) | STARTED | Final Cohort (Linaclotide 72 μg) | 6 | |
| Post-Treatment Period (1 Week) | STARTED | Placebo Pooled | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04110145/flow